Kristin Yarema's most recent trade in Poseida Therapeutics Inc was a trade of 615,836 Common Stock done . Disclosure was reported to the exchange on Jan. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Kristin Yarema | President and CEO | 08 Jan 2025 | 615,836 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Kristin Yarema | President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 498,325 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Kristin Yarema | President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 345,200 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Kristin Yarema | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 345,200 | 345,200 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | Kristin Yarema | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 250,000 | 606,836 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Kristin Yarema | President, Cell Therapy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2023 | 498,325 | 498,325 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Kristin Yarema | President, Cell Therapy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Apr 2023 | 356,836 | 356,836 | - | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Kristin Yarema | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 85,592 | 85,592 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Kristin Yarema | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 45,533 | 171,415 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Kristin Yarema | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 14.55 per share. | 18 May 2021 | 761 | 91,528 (0%) | 0% | 14.6 | 11,073 | Common Stock |
| Atara Biotherapeutics Inc | Kristin Yarema | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 52,862 | 52,862 | - | - | Employee Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Kristin Yarema | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 35,021 | 92,289 (0%) | 0% | 0 | Common Stock |